AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02344355
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.~After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide.
Trial: NCT05639803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5ml/vial
Trial: NCT00720811
Drug: Artemether-lumefantrine combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20/120mg Artemether-lumefantrine 4-35 months: 1 tablet twice daily for 3 days; 36-59 months: 2 tablets twice daily for 3 days
Trial: NCT00720811
Drug: Artemether-lumefantrine combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20/120mg tablet arthermether-lumefantrine 4-35months: 1x2; 36-59months: 2x2
Trial: NCT01766843
Drug: Seretide Diskus and charcoal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations as a single dose
Trial: NCT01766843
Drug: SF Easyhaler and charcoal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations as a single dose
Trial: NCT03997838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of 0 mg of VVZ-149
Trial: NCT01036139
Drug: BF2.649 (pitolisant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
Trial: NCT03115515
Drug: levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To compare two different methods of adjusting thyroid hormone replacement during pregnancy to maintain TSH within the normal reference range for pregnancy.
Trial: NCT01872754
Drug: 1: Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1: Remifentanil group The infusion of Remifentanil by TCI begins at distance from the introduction of fiberoptic. The effect site target is 4 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 1 ng / ml effect site concentration) separated by 1 minute intervals until an OAAS score of 4 and respiratory frequency range between 10 and 20 cycles per minute.
Trial: NCT04269187
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline oral 200 mg daily for 12 days
Trial: NCT03378934
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for 12±1 weeks.
Trial: NCT01923974
Drug: Melatonin 10 mg
RxNorm normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01923974
Drug: Melatonin 100 mg
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01923974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00290628
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03933631
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone acetate ophthalmic suspension 1%
Trial: NCT01647880
Drug: Verum arm receiving Gilenya®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01647880
Drug: Active Comparator receiving Extavia®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01642667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02572687
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02241772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02965456
Drug: IDP 121 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.
Trial: NCT02965456
Drug: IDP-121 Vehicle Lotion
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
Trial: NCT04043104
Drug: AAV2hAQP1: 1 x 10^11 vg/gland (single gland)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^11 vg/gland
Trial: NCT04043104
Drug: AAV2hAQP1: 3 x 10^10 vg/gland (both glands)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^10 vg/gland
Trial: NCT04043104
Drug: AAV2hAQP1: 3 x 10^11 vg/gland (single gland)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-parotid administration of AAV2hAQP1 of via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^11 vg/gland
Trial: NCT04043104
Drug: AAV2hAQP1: 1 x 10^11 vg/gland (both glands)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^11 vg/gland
Trial: NCT04043104
Drug: AAV2hAQP1: 1 x 10^12 vg/gland (single gland)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^12 vg/gland
Trial: NCT04043104
Drug: AAV2hAQP1: 3 x 10^11 vg/gland (both glands)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^11 vg/gland
Trial: NCT04043104
Drug: AAV2hAQP1: 3 x 10^12 vg/gland (single gland)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^12 vg/gland
Trial: NCT04043104
Drug: AAV2hAQP1: 1 x 10^12 vg/gland (both glands)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^12 vg/gland
Trial: NCT03325803
Drug: MAL application
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
Trial: NCT03948620
Drug: Macrolides
RxNorm normalized name: Macrolides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macrolide antibiotics, including erythromycin, clarithromycin and azithromycin. Prescriptions of macrolides will be identified using a drug code list based on the British National Formulary (chapter 5.1.5) and the date of the first prescription was used as the index date of exposure.
Trial: NCT03948620
Drug: Penicillins
RxNorm normalized name: (INACTIVE) PENICILLINS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The comparison group consists of children whose mother were prescribed penicillins during pregnancy. Prescriptions of penicillins will be identified using a drug code list based on the British National Formulary (chapter 5.1.1) and the date of the first prescription will be used as the index date of exposure.
Trial: NCT04044287
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy
Trial: NCT03702374
Drug: Combined antioxidant therapy
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide 20mg), copper (copper sulfate 1mg), taken once a day for 12 months
Trial: NCT03748212
Drug: D935 Cap. 1T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration under fed condition
Trial: NCT03748212
Drug: CKD-385 Tab. 1T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration under fed condition
Trial: NCT03262038
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively as well as IV every 6 hrs for 24 hours postoperatively.
Trial: NCT01217411
Drug: Gamma-Secretase Inhibitor RO4929097
RxNorm normalized name: .GAMMA.-OCTALACTONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03944876
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml Sodium Chloride (NaCl) 0.9% Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
Trial: NCT02635672
Drug: VIP152 (BAY 1251152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose of Cohort 1 will be 5 mg IV (30 minute infusion) fixed dose once weekly (5 mg/week) for 21 day cycles.
Trial: NCT02635672
Drug: VIP152 (BAY 1251152) 30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg IV (30 minute infusion) fixed dose once weekly of a 21 day cycle.
Trial: NCT02635672
Drug: VIP152 (BAY 1251152) 15 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose of Cohort 3 will be 15 mg IV (30 minute infusion) fixed dose once weekly (15 mg/week) for 21 day cycles.
Trial: NCT02362412
Drug: FK949E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A tablet containing 50 mg or 150 mg of quetiapine taken orally.
Trial: NCT02738697
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8\~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
Trial: NCT03997734
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single and repeated dosing
Trial: NCT00265642
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet per day during 2 years
Trial: NCT00641212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01523431
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The LV dosage will remain the standard.
Trial: NCT01505426
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01505426
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02623439
Drug: Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
Trial: NCT00816673
Drug: placebo Circadin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tabs of Prolonged release melatonin
Trial: NCT04082442
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo.
Trial: NCT00863460
Drug: MTX based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58\&59 and days79\&80
Trial: NCT02834442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04359680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally twice daily for six weeks
Trial: NCT00520572
Drug: AZD9056
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00520572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00409227
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once a day for 3 months or stone free
Trial: NCT00660959
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT02504775
Drug: Mejoral® 500 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg tablet of paracetamol
Trial: NCT02504775
Drug: Tylenol® Caplets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg tablet of paracetamol
Trial: NCT03142204
Drug: [18F]F-AraG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose IV injection of \[18F\]F-AraG for each imaging day.
Trial: NCT01230814
Drug: Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-Penotran® Forte (active ingredient Metronidazole \& Miconazole Nitrate), co-formulated vaginal suppositories containing metronidazole 750 mg with miconazole 200 mg and excipients (Witepsol S 55). Witepsol S 55 is a hard fat suppository base. Such bases consist mainly of triglyceride esters of the higher saturated fatty acids along with varying proportions of mono- and diglycerides. 117 subjects receive nightly for 5 consecutive night each month.
Trial: NCT01230814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaginal suppositories, identical in appearance to the active product; contains Witepsol S 55, Titanium Dioxide and D+C yellow #10 with no metronidazole or miconazole.117 subjects receive nightly for 5 consecutive nights each month.
Trial: NCT00919490
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, see arms for interventional description
Trial: NCT00919490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, see arms for interventional description.
Trial: NCT01748552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as capsules
Trial: NCT01748552
Drug: LY2922083
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as capsules
Trial: NCT03387579
Drug: Smoflipid 20% Lipid Emulsion for Injection
RxNorm normalized name: Smoflipid 20% Lipid Emulsion for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lipid containing soy, MCT, olive, and fish oils at goal doses of 3 g/kg/day
Trial: NCT03387579
Drug: Intralipid, 20% Intravenous Emulsion
RxNorm normalized name: Intralipid, 20% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lipid emulsion of 20% soy oil at goal doses of 1 g/kg/day
Trial: NCT03387579
Drug: Intralipid, 20% Intravenous Emulsion
RxNorm normalized name: Intralipid, 20% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lipid emulsion of 20% soy oil at goal doses of 2-3 g/kg/day
Trial: NCT02224079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxypropyl-beta-cyclodextrin (HPβCD)
Trial: NCT00432991
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL, IM (in the muscle), one time
Trial: NCT02598999
Drug: bLF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for inhalation administered through nebulization
Trial: NCT02598999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for inhalation administered through nebulization, Sodium Chloride 0.9%
Trial: NCT04294160
Drug: LTT462
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule for oral use
Trial: NCT01830101
Drug: TMZ plus concurrent re-irradiation
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03240055
Drug: spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The spinal puncture was performed with a 25 G Sprotte needle at the L3-4 or L2-3 interspinous space. Hyperbaric bupivacaine 0.5% (3 ml) was administered into the spinal space. Hyperbaric bupivacaine is obtained through the addition of glucose 10% (1ml) to bupivacaine 0.75% (2ml). Cerebrospinal fluid aspiration (0.1 ml) was done to confirm correct needle placement before and after spinal drug administration. Whereafter the patient was turned rapidly to the supine position, sensory anesthesia height was evaluated bilaterally using a pinprick test with the sharp tip of a safety pin every 1 min until 15 min after the initiation of the spinal anesthesia, bed tilting (upwards, horizontal, or downwards) was performed until bilateral sensory anesthesia level was confirmed to remain at the T4-T6 level
Trial: NCT04432298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile liquid for injection
Trial: NCT01818648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
Trial: NCT01038895
Drug: Experimental
RxNorm normalized name: WA-001 Experimental Soil Surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet; 300 mg; od; 3 months
Trial: NCT02950974
Drug: Sterofundin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid loading
Trial: NCT00548691
Drug: Standard Medical Care (SMC)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04171310
Drug: SAR442168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:oral solution Route of administration: Oral
Trial: NCT02058407
Drug: GSK2793660 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear, colourless solution at a unit dose strength of 0.1 mg/mL, in a glass bottle
Trial: NCT02058407
Drug: GSK2793660 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Size zero swedish orange capsule at a unit dose of 3 mg, 10 mg, 20 mg and 50 mg
Trial: NCT02058407
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to GSK2793660 solution
Trial: NCT02058407
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to GSK2793660 capsule
Trial: NCT00001476
Drug: Gene Therapy Method for CGD
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01433081
Drug: Placebo infusion of .9 normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of .9 normal saline
Trial: NCT01431092
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Circadin and placebo are encapsulated in lactose containing gelatin capsules to optimize the blinding.
Trial: NCT01431092
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prolonged-release melatonin (Circadin®) 2 mg, once daily, 1-2 hours before bedtime.
Trial: NCT03390673
Drug: HD204
RxNorm normalized name: Hydrocodone/Acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
Trial: NCT03093870
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Trial: NCT03093870
Drug: Placebo (for Varlitinib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death
Trial: NCT01103518
Drug: Ethinyl Estradiol + Cyproterone acetate
RxNorm normalized name: cyproterone / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinyl Estradiol (0.035mg) + Cyproterone acetate (2mg), coated tablets. Each treatment cycle consists of one tablet, once per day for 21 days followed by a 7-day rest period. A total of 4 treatment cycles will be completed during the study treatment period.
Trial: NCT01225224
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01293955
Drug: JOINS 200mg
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet at each time, 3 times a day
Trial: NCT01293955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo of Joins 200mg
Trial: NCT01531829
Drug: Low Molecular Weight Heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1ml/10kg,q12h,5-7 days
Trial: NCT04675619
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment
Trial: NCT04281576
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000mg/m\^2 taken by mouth, twice daily on day 1-14, 3 weeks per cycle
Trial: NCT00004061
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01345942
Drug: RO5428029
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT03303066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02810132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See above
Trial: NCT01682720
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Trial: NCT01682720
Drug: Placebo to match SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match SOF administered orally once daily
Trial: NCT01682720
Drug: Placebo to match RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match RBV administered orally in a divided daily dose
Trial: NCT02654483
Drug: VPD-737
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPD-737 inhibits the receptor neurokinin-1.